FDAsafety guidance65% confidence
FDA AP — JAKAFI XR (ORIG)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Incyte Corporation.
Regulatory Analysis
Application NDA217180. Sponsor: INCYTE CORP. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: RUXOLITINIB PHOSPHATE.
Supporting Context
- Therapeutic area
- Hematology · JAK Inhibitor
- Sub-indication
- General
Related signal: Apotex Inc. Submits ANDA for Ruxolitinib